From GlobeNewswire: 2024-05-21 03:30:00

Custom Market Insights released a research report on the Non-Small-Cell Lung Cancer Drug Market, projecting a substantial growth from USD 31,614.8 Million in 2023 to an estimated USD 68,888.6 Million by 2033, with a CAGR of 8.1%. Advancements in targeted therapies, rising NSCLC incidence, and personalized medicine approaches are key factors driving market growth.

In 2023, Novocure’s Tumor Treating Fields combined with standard therapies for stage 4 NSCLC met its primary endpoint, showing promise for patients who progressed after platinum-based therapy. AbbVie’s FDA-approved T-cell engaging bispecific antibody offers new treatment options for relapsed or refractory DLBCL and HGBL patients.

The COVID-19 pandemic disrupted healthcare services, causing delays in cancer screenings and clinical trials for NSCLC drugs. As services resume, telemedicine, early detection efforts, and research continuity play integral roles in delivering care, advancing treatment options, and driving recovery in the NSCLC drug market.

Key questions the report answers include the market size, growth rate, driving factors, top companies, market categories, fastest-growing segments, essential players in the value chain, and how to obtain a free copy of the Non-Small-Cell Lung Cancer Drug market sample report for insights. Request a customized report for tailored research and analysis.



Read more at GlobeNewswire: [Latest] Global Non-Small-Cell Lung Cancer Drug Market